AZD-5438Potent CDK1/2/9 inhibitor CAS# 602306-29-6 |
- LDC000067
Catalog No.:BCC5452
CAS No.:1073485-20-7
- BS-181
Catalog No.:BCC1439
CAS No.:1092443-52-1
- LEE011 succinate hydrate
Catalog No.:BCC4103
CAS No.:1374639-79-8
- CDK9 inhibitor
Catalog No.:BCC1465
CAS No.:1415559-43-1
- Roscovitine (Seliciclib,CYC202)
Catalog No.:BCC1105
CAS No.:186692-46-6
- P276-00
Catalog No.:BCC4415
CAS No.:920113-03-7
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 602306-29-6 | SDF | Download SDF |
PubChem ID | 16747683 | Appearance | Powder |
Formula | C18H21N5O2S | M.Wt | 371.46 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Solubility | DMSO : 100 mg/mL (269.21 mM; Need ultrasonic) | ||
Chemical Name | 4-(2-methyl-3-propan-2-ylimidazol-4-yl)-N-(4-methylsulfonylphenyl)pyrimidin-2-amine | ||
SMILES | CC1=NC=C(N1C(C)C)C2=NC(=NC=C2)NC3=CC=C(C=C3)S(=O)(=O)C | ||
Standard InChIKey | WJRRGYBTGDJBFX-UHFFFAOYSA-N | ||
Standard InChI | InChI=1S/C18H21N5O2S/c1-12(2)23-13(3)20-11-17(23)16-9-10-19-18(22-16)21-14-5-7-15(8-6-14)26(4,24)25/h5-12H,1-4H3,(H,19,21,22) | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | Potent inhibitor of cyclin-dependent kinase (cdk) 1, 2 and 9 (IC50 values are 16, 6 and 20 nM respectively). Exhibits antiproliferative activity in human tumor cell lines. Blocks cell cycling at G2-M, S and G1 phases; reduces the proportion of actively cycling cells in vivo. |
AZD-5438 Dilution Calculator
AZD-5438 Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 2.6921 mL | 13.4604 mL | 26.9208 mL | 53.8416 mL | 67.302 mL |
5 mM | 0.5384 mL | 2.6921 mL | 5.3842 mL | 10.7683 mL | 13.4604 mL |
10 mM | 0.2692 mL | 1.346 mL | 2.6921 mL | 5.3842 mL | 6.7302 mL |
50 mM | 0.0538 mL | 0.2692 mL | 0.5384 mL | 1.0768 mL | 1.346 mL |
100 mM | 0.0269 mL | 0.1346 mL | 0.2692 mL | 0.5384 mL | 0.673 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
AZD5438 is a potent small molecule inhibitor of cyclin-dependent kinase (CDK) 1, 2 and 9 with half maximal inhibitory concentration IC50 of 16 nmol/L, 6 nmol/L and 20 nmol/L respectively. AZD5438 has also been found to potently inhibit the human cyclin E/CDK2 complex, the cyclin B1/CDK1 complex and the cyclin A/CDK2 complex with IC50 of 0.006 μM, 0.016 μM and 0.045 μM respectively. In previous studies, AZD5438 has exhibited significant anti-proliferative activity in a few human tumor cell lines with IC50 ranging from 0.2 μmol/L to 1.7 μmol/L, in which the phosphorylation of a few proteins, including CDK substrates pRb, nucleolin, protein phosphatase 1a and RNA polymerase II COOH-terminal domain, and cell cycling at G2-M, S and G1 phases were inhibited.
References:
[1]Camidge DR1, Smethurst D, Growcott J, Barrass NC, Foster JR, Febbraro S, Swaisland H, Hughes A. A first-in-man phase I tolerability and pharmacokinetic study of the cyclin-dependent kinase-inhibitor AZD5438 in healthy male volunteers. Cancer Chemother Pharmacol. 2007 Aug;60(3):391-8. Epub 2006 Nov 18.
[2]Byth KF, Thomas A, Hughes G, Forder C, McGregor A, Geh C, Oakes S, Green C, Walker M, Newcombe N, Green S, Growcott J, Barker A, Wilkinson RW. AZD5438, a potent oral inhibitor of cyclin-dependent kinases 1, 2, and 9, leads to pharmacodynamic changes and potent antitumor effects in human tumor xenografts. Mol Cancer Ther. 2009 Jul;8(7):1856-66. doi: 10.1158/1535-7163.MCT-08-0836. Epub 2009 Jun 9.
- Oleanolic acid-3-O-beta-D-glucopyranosyl (1→2)-alpha-L-arabinopyranoside
Catalog No.:BCN1406
CAS No.:60213-69-6
- Altamycin A
Catalog No.:BCN1823
CAS No.:60202-22-4
- Coptisine chloride
Catalog No.:BCN6321
CAS No.:6020-18-4
- 1,2-dihydroxy-3-methyl-anthracene-9,10-dione
Catalog No.:BCN1404
CAS No.:602-63-1
- Thiocolchicoside
Catalog No.:BCN8442
CAS No.:602-41-5
- Taspine
Catalog No.:BCN6956
CAS No.:602-07-3
- Licoflavonol
Catalog No.:BCN6828
CAS No.:60197-60-6
- Methyl 15-hydroxy-7-oxodehydroabietate
Catalog No.:BCN7674
CAS No.:60188-95-6
- Corypalmine
Catalog No.:BCN4111
CAS No.:6018-40-2
- Arecaidine hydrochloride
Catalog No.:BCN8530
CAS No.:6018-28-6
- Sodium 4-Aminosalicylate
Catalog No.:BCC4609
CAS No.:6018-19-5
- TWS119
Catalog No.:BCC4512
CAS No.:601514-19-6
- Tetrahydropalmatine Hydrochloride
Catalog No.:BCN8335
CAS No.:6024-85-7
- (±)-Nipecotic acid
Catalog No.:BCC6576
CAS No.:60252-41-7
- Ethyl(1-hydroxy-4-oxocyclohexa-2,5-dien-1-yl)acetate
Catalog No.:BCN1405
CAS No.:60263-06-1
- H-D-HoSer-OH
Catalog No.:BCC3243
CAS No.:6027-21-0
- Aspalathin
Catalog No.:BCC8122
CAS No.:6027-43-6
- Guanosine-2'(3')-monophosphate disodium salt
Catalog No.:BCC3608
CAS No.:6027-83-4
- Guvacine hydrochloride
Catalog No.:BCC6574
CAS No.:6027-91-4
- Gestodene
Catalog No.:BCC4490
CAS No.:60282-87-3
- 7-Angeloylretronecine
Catalog No.:BCN2036
CAS No.:6029-82-9
- Rinderine
Catalog No.:BCN1971
CAS No.:6029-84-1
- Latifoline
Catalog No.:BCN1978
CAS No.:6029-86-3
- Fulvine
Catalog No.:BCN2082
CAS No.:6029-87-4
AZD5438, a potent oral inhibitor of cyclin-dependent kinases 1, 2, and 9, leads to pharmacodynamic changes and potent antitumor effects in human tumor xenografts.[Pubmed:19509270]
Mol Cancer Ther. 2009 Jul;8(7):1856-66.
Deregulation of the cell cycle has long been recognized as an essential driver of tumorigenesis, and agents that selectively target key cell cycle components continue to hold promise as potential therapeutics. We have developed AZD5438, a 4-(1-isopropyl-2-methylimidazol-5-yl)-2-(4-methylsulphonylanilino) pyrimidine, as a potent inhibitor of cyclin-dependent kinase (cdk) 1, 2, and 9 (IC(50), 16, 6, and 20 nmol/L, respectively). In vitro, AZD5438 showed significant antiproliferative activity in human tumor cell lines (IC(50) range, 0.2-1.7 micromol/L), causing inhibition of the phosphorylation of cdk substrates pRb, nucleolin, protein phosphatase 1a, and RNA polymerase II COOH-terminal domain and blocking cell cycling at G(2)-M, S, and G(1) phases. In vivo, when orally administered at either 50 mg/kg twice daily or 75 mg/kg once daily, AZD5438 inhibited human tumor xenograft growth (maximum percentage tumor growth inhibition, range, 38-153; P < 0.05). In vivo, AZD5438 reduced the proportion of actively cycling cells. Further pharmacodynamic analysis of AZD5438-treated SW620 xenografts showed that efficacious doses of AZD5438 (>40% tumor growth inhibition) maintained suppression of biomarkers, such as phospho-pRbSer(249)/Thr(252), for up to 16 hours following a single oral dose. A comparison of different schedules indicated that chronic daily oral dosing provided optimal cover to ensure antitumor efficacy. These data indicate that broad cdk inhibition may provide an effective method to impair the dysregulated cell cycle that drives tumorigenesis and AZD5438 has the pharmacologic profile that provides an ideal probe to test this premise.